QR Code

Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist

Background In contrast to immune checkpoint inhibitors, the use of antibodies as agonists of immune costimulatory receptors as cancer therapeutics has largely failed. We sought to address this problem using a new class of modular synthetic drugs, termed tumor-targeted immune cell agonists (TICAs), b...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Sailaja Battula, Kristen Hurov, Johanna lahdenranta, Gemma Mudd, Punit Upadhyaya, Elizabeth Repash, Julia Kristensson, Marianna Kleyman, Jessica Kublin, Liuhong Chen, Eric Haines, Kevin McDonnell, Philip Brandish, Nicholas Keen, Rachel Dods, Rachid Lani, Katerine Van Rietschoten, Tom Stephen, Fanglei You
Hōputu: Artigo
Reo:Inglês
I whakaputaina: BMJ Publishing Group 2021-01-01
Rangatū:Journal for ImmunoTherapy of Cancer
Urunga tuihono:https://jitc.bmj.com/content/9/1/e001762.full
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite